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A B S T R A C T
This study aimed to assess the robustness of using a spray drying approach and formulation design in producing
inhalable phage powders. Two types of Pseudomonas phages, PEV2 (Podovirus) and PEV40 (Myovirus) in two
formulations containing diﬀerent amounts of trehalose (70% and 60%) and leucine (30% and 40%) were stu-
died. Most of the surface of the produced powders was found to be covered in crystalline leucine. The powders
were stored at 4 °C and 20 °C under vacuum. The phage stability and in vitro aerosol performance of the phage
powders were examined on the day of production and after 1, 3 and 12months of storage. A minor titer loss
during production was observed for both phages (0.2–0.8 log10 pfu/ml). The storage stability of the produced
phage powders was found to be phage and formulation dependent. No further reduction in titer occurred for
PEV2 powders stored at 4 °C across the study. The formulation containing 30% leucine maintained the viability
of PEV2 at 20 °C, while the formulation containing 40% leucine gradually lost titer over time with a storage
reduction of ∼0.9 log10 pfu/ml measured after 12months. In comparison, the PEV40 phage powders generally
had a∼ 0.5 log10 pfu/ml loss upon storage regardless of temperature. When aerosolized, the total in vitro lung
doses of PEV2 were of the order of 107 pfu, except the formulation containing 40% leucine stored at 20 °C which
had a lower lung dose. The PEV40 powders also had lung doses of 106–107 pfu. The results demonstrate that
spray dried Myoviridae and Podoviridae phage in a simple formulation of leucine and trehalose can be success-
fully stored for one year at 4 °C and 20 °C with vacuum packaging.
1. Introduction
Phage therapy has recently been demonstrated as a promising al-
ternative to conventional antibiotics to treat and prevent pulmonary
infections caused by multidrug resistance (MDR) bacterial strains
[1–7]. Early research on pulmonary delivery of phage was conﬁned to
liquid sprays using intranasal instillation and nebulization as minimum
formulation development was required [8]. Nebulization has been a
popular choice because of its high eﬃciency in delivering phage to the
lung at a low inhalation ﬂow rate and minimum requirement in in-
halation coordination [3,9]. Recently, increasing eﬀorts have been
devoted into developing respirable phage powder formulations for
improved storage stability, easy transport and administration. Various
dry powder formulation techniques, including freeze drying followed
by deagglomeration in a mixer mill [10], spray drying [11–14] and
spray freeze drying [13], have been reported to be capable of producing
inhalable phage dry powders. Among them, the spray drying technique
is favorable because it is a single-step method to produce ﬁne phage
powders with the potential of causing only moderate titer loss (≤l log10
pfu/ml) upon processing. Yet, there has been no report on the eﬀect of
temperature on long term storage of the spray dried phage powders.
This study is the ﬁrst to assess the storage stability, in terms of both the
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phage viability and in vitro aerosol performance, of the produced phage
powders at room temperature and under refrigeration.
As phage are essentially composed of a stable protein capsule en-
closing genomic materials, current solid-state phage formulation stra-
tegies have largely adapted the knowledge obtained in the development
of protein-based pharmaceuticals and viral vaccines [15,16]. While a
1–10 log10 pfu titer reduction was noted when phage was dried with
buﬀer only [17,18], addition of sugars, such as sucrose [17,19], lactose
[10,17] and trehalose, provided excellent protection for phages during
the drying process and storage. It is believed that the high transition
temperatures (Tg) of these sugars (60 °C for sucrose, 108 °C for lactose
and 115 °C for trehalose) and/or their capability as a water substitute
play important roles in stabilizing protein/phage in the solid-state [20].
Upon drying, the hydrogen bonding between water molecules and the
phage protein coat could be replaced by bonding with the excipients to
prevent protein unfolding and immobilize phages within the amor-
phous glassy matrix [20]. However, crystallization of trehalose kills
phage [21]. Therefore, it is crucial for amorphous sugar components to
remain well below the glass transition temperature during storage.
In addition to the sugar, L-leucine has been included as a second
excipient to improve the powder dispersibility for pulmonary delivery
[11,14]. L-leucine also has surfactant-like properties, in that it is surface
active and crystallizes early due to low solubility, thus forming the
outer shell of the particles, which could encapsulate the phage and
other excipients. The in vitro aerosol performance of a trehalose-leucine
formulation produced by Matinkhoo et al. [11] was not assessed.
However, they showed formulations with a third excipient, either a
surfactant or casein sodium salt could achieve an in vitro lung mass up
to 82.7% of the loaded mass, with a lung dose of the order of 106 pfu/
mg. These spray dried phage powders were stable with less than 0.15
titer loss under refrigeration for a period of three months. In our recent
study [14], we showed that sugar (trehalose and/or mannitol) powder
matrix containing 20% leucine could achieve reasonably good aerosol
performance (∼40% ﬁne particle fraction based on the recovered
phage) with satisfactory stability such that no further titer loss was
noted after 12months storage at RH≤ 22% and 4 °C (≤1 log10 pfu/ml
loss upon storage). Vandenheuvel et al. [21] also showed that phages
embedded in trehalose powders were most stable when stored at 4 °C
and 0% RH. A 54% RH storage condition caused powder crystallization
and signiﬁcant phage inactivation, with the impact being more pro-
nounced for large phage virions (Myovirus romulus) than smaller one
(Podovirus LUZ19). Thermal instability was also reported for the phage
powders stored at 25 °C [21]. Since dry powder inhaler products are
usually administrated at room temperature and cold-chain storage is
limited in most developing countries, more information on the stability
of phage powders at higher temperatures is important for future de-
velopment of phage powder formulations.
Although leucine is a well-studied aerosolization enhancer, its
capability of protecting spray dried powders against moisture was re-
cently reported [22,23]. Li et al. [22] showed an addition of 10–20wt%
of leucine could minimize the moisture induced deterioration of the
aerosol performance of spray dried disodium cromoglycate powders,
which absorbed a signiﬁcant amount of water without recrystallization
under higher relative humidity (≥60%). In their follow-up work [23]
on spray dried salbutamol sulfate, which recrystallized at high RH
condition (≥60%), a higher mass fraction (≥40%) of leucine was re-
quired to eliminate the eﬀect of moisture on the aerosolization per-
formance. Based on a mechanistic model and experimental results, Feng
et al. [24] suggested that a minimum leucine threshold must be ex-
ceeded to obtain crystalline leucine to form low-density and well-dis-
persing particles. For trehalose-leucine powders produced with a Büchi
B-90 Nano Spray Dryer, a mass fraction≥ 25% of leucine at a total feed
concentration of 28.9mg/mL was required to ensure 100% leucine
crystallinity. Our previous studies [13,14] suggested that the amount of
leucine (20%) may not be suﬃcient to form a crystalline shell to protect
the amorphous trehalose. In the present study, we extended our work to
investigate the eﬀects of leucine content and storage temperature on
the long term stability of spray dried phage powders. In addition, two
types of Pseudomonas phages, PEV2 (Podovirus) and PEV40 (Myovirus),
were studied to elucidate the robustness of the spray drying approach
and formulation design in producing inhalable phage powders. The
phage stability and in vitro aerosol performance of the powders were
assessed after 0, 1, 3 and 12months storage at 4 and 20 °C with vacuum
packaging. This is the ﬁrst successful study demonstrating the long-
term room temperature stability of spray dried, inhalable phage pow-
ders with less than 1 log10 pfu/ml loss and no deterioration in the in
vitro aerosol performance after one year.
2. Methods and materials
2.1. Materials
Two Pseudomonas lytic phages of diﬀerent morphologies, a N4-type
Podovirus (PEV2, 1.4× 1011 pfu/ml stock titer) and a PB1-like Myovirus
(PEV40, 2.2× 1010 pfu/ml stock titer), were used. The phages were
isolated from the sewage treatment plant in Olympia, WA, USA by
students in the Evergreen State College Phage Laboratory. Phage stocks
stored in salt-magnesium buﬀer (SMB, 5.2 g/l sodium chloride, 2 g/l
magnesium sulfate, 6.35 g/l Tris-HCL, 1.18 g/l Tris base and 0.01%
gelatin) were supplied via AmpliPhi Biosciences (AmpliPhi Biosciences
AU, NSW Australia) and used without further puriﬁcation. D-(+)-tre-
halose dihydrate and L-leucine (Sigma–Aldrich, NSW, Australia) were
co-spray dried with phage to form a powder matrix to protect the phage
particles. Adapting the mathematical model developed by Feng et al.
[24] for a Büchi 290 spray dryer, it was estimated that a leucine content
of≥30% was required to form a fully crystalline leucine shell under the
spray drying conditions used in our previous studies [13,14] to produce
the phage powders. Table 1 shows the compositions of the four for-
mulations prepared in the present study.
2.2. Powder preparation
The powder preparation was the same as that documented in our
previous study [14]. Brieﬂy, an aliquot of 500 µl of the phage stock was
added to 50ml excipient solution of trehalose and leucine at a total
solid content of 20mg/ml prior to spray drying. The mixtures were
spray dried using a Büchi 290 spray dryer (Buchi Labortechnik AG,
Flawil, Switzerland) using an open-loop setting at a drying gas ﬂow rate
of 35m3/h, atomizing air ﬂow rate of 0.742m3/h, and inlet tempera-
ture of 60 °C with a liquid feed rate of 1.8ml/min. The outlet tem-
perature was between 40 and 45 °C. The produced powders were ali-
quoted into scintillation vials and packed inside a vacuum sealed bag
using a Westinghouse vacuum food sealer inside a relative humidity
controlled chamber (RH < 20%). The vacuum packed vials were then
stored at 4 and 20 °C before use.
2.3. Powder characterization
2.3.1. Particle morphology
Morphologies of the spray dried powders were examined using a
ﬁeld emission scanning electron microscope (SEM) (Zeiss Ultra Plus
Table 1
Formulation compositions.
Formulation # Phage Starting titer (pfu/ml) Contents (w/w %)
Trehalose Leucine
F1 PEV2 1.4×109 70 30
F2 PEV2 1.4×109 60 40
F3 PEV40 2.2×108 70 30
F4 PEV40 2.2×108 60 40
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HD, Oberkochen, Germany) at 3 kV beam accelerating voltage. The
samples were scattered on a carbon tape and sputter coated with 15 nm
of gold using a K550X sputter coater (Quorum Emitech, Kent, UK) be-
fore imaging.
2.3.2. Particle size distribution
Optical particle size distributions of the powder formulations were
measured using a Malvern Mastersizer 2000 (Malvern Instruments,
UK). The powders were dispersed through the measurement window
with compressed air at 350 kPa using a Scirocco 2000 dry powder
module (Malvern Instruments, UK). The real, imaginary and dispersant
(air) refractive indices were set at 1.52, 0.1 and 1.0, respectively. All
measurements were done in triplicate. The size distribution was ex-
pressed by the volume median diameter (VMD), and span deﬁned as the
diﬀerence in the particle diameters at 10% and 90% cumulative volume
divided by the VMD.
2.3.3. Particle crystallinity
Powder crystallinity was evaluated using an X-ray diﬀractometer
(Model D5000; Siemens, Munich, Germany) under ambient condition.
Samples were subjected to Cu Ka radiation at 30mA and 40 kV, and the
scattered intensity was detected with an angular increment rate of 0.04°
2θ/s from 5° to 40°.
The crystalline and amorphous components of the spray dried
powders were also determined using a custom built dispersive Raman
system with the methodology detailed in Vehring et al. [25] The Raman
system utilized a 671 nm diode-pumped solid-state laser (Ventus 671,
Laser Quantum, UK) with maximum output power of 500mW. Brieﬂy,
the powder samples were ﬁrst loaded into a 0.2 µl conical sample
holder and kept under a nitrogen atmosphere during the measurement.
All spectra were acquired at a temperature of 21 ± 1 °C and a relative
humidity of less than 3%. Reference spectra of crystalline L-leucine and
trehalose dihydrate were collected from raw material. Amorphous tre-
halose was obtained by spray drying. The amorphous leucine reference
spectrum was approximated by measuring the saturated aqueous so-
lution of leucine and then subtracting the spectrum of water. Char-
acteristic peaks of the reference spectra were used to determine the
solid phase of each component.
2.3.4. Thermal analysis
The thermal properties of the powders were analyzed using a dif-
ferential scanning calorimeter and thermogravimetric analysis (Mettler
Toledo, Greifensee, Switzerland). For DSC measurement, each sample
(5 ± 1mg) was weighed in an aluminium crucible which was then
crimped to a perforated lid and heated from 30 to 300 °C at a rate of
10 °C/min under 250 cm3/min nitrogen purge. For TGA measurements
each sample (5 ± 1mg) was weighed in an alumina crucible and he-
ated from 30 to 400 °C at a rate of 10 °C/min with dynamic nitrogen
ﬂow.
2.3.5. Moisture sorption
The moisture sorption proﬁles of the powders were analyzed using a
DVS instrument (DVS-Intrinsic, Surface Measurement Systems, London,
UK). Each sample (∼5 mg) was subjected to a dual moisture ramping
cycle of 0–90% RH at a step increase of 10%. The moisture content at
each relative humidity was determined when it changed by less than
0.02% per minute.
2.3.6. Particle surface components
X-ray photoelectron spectroscopy (XPS) was employed to study the
chemical composition of the particle surface. XPS analysis was per-
formed with an AXIS Nova Spectrometer (Kratos Analytical Ltd.,
Manchester, UK), equipped with a monochromated Al Ka source at a
power of 180W (12mA, 15 kV). Powders were ﬁlled into shallow wells
of custom-made sample holders, and an approximate area of
0.3 mm×0.7mm was analyzed. An electron ﬂood gun in combination
with a magnetic immersion lens was used to compensate for charging of
the samples during analysis. The remaining oﬀsets due to charge neu-
tralization were corrected using a reference binding energy value of
285.0 eV for the C 1s peak of aliphatic hydrocarbon. The pressure in the
main vacuum chamber during analysis was approx. 10−6 Pa. Spectra
were recorded at a nominal photoelectron emission angle of 0° w.r.t.
the surface normal. The sampling depth is in the range of 0–10 nm as
the microscopic emission angle is ill-deﬁned in the case of particles
(ranging from 0° to 90°). The elemental compositions of powder sam-
ples were determined based on survey spectra (160 eV pass energy)
using sensitivity factors provided by the manufacturers. High-resolution
spectra of individual peaks were recorded at 20 eV pass energy which
resulted in a peak width of typically 0.8–1.0 eV. In order to calculate
relative molar fraction of trehalose and leucine on the surface of the
composite particles, reference data were ﬁrstly obtained from two pure
compounds. The data based on the composite particles were then
compared with the reference data, and molar percent of each compo-
sition were estimated as follows: The atomic concentration of each
element (i.e. C, O, N and S) in the composite particles was assumed to
be a linear combination of the corresponding concentration in the pure
compounds, appropriately scaled and normalized using the number of
respective atoms in one molecule of trehalose or leucine. Element ni-
trogen (N) is unique in leucine molecules. Thus, based on the experi-
mentally determined N atomic concentration, the molar percent of
trehalose and leucine on the surface of particles was estimated. The
accuracy associated with quantative XPS is ca. 10–15%. Precision (i.e.
reproducibility) depends on the signal to noise ratio but is usually much
better than 5%. The latter is relevant when comparing similar samples
as in the case of this study.
2.4. Powder stability
Freshly spray dried phage powder was transferred in a Perspex box
at a RH≤ 17% into two 30ml glass vials which were loosely capped
and placed in a vacuum sealed bag. The samples were then stored at 4
and 20 °C for up to a year. The phage viability and powder were ex-
amined after 0, 1, 3 and 12months storage. An amount of 15mg of
powder stored at each condition was dissolved in 300 µl SMB to give a
concentration of 50mg/ml. The number of viable phages in the powder
samples was determined by the Miles-Misra surface droplet technique
[26]. Serial dilutions, 1:10, were performed by adding 20 µl samples to
180 µl SMB. A volume of 200 µl host bacteria containing ∼2×109
colony forming units (cfu) was mixed with 5ml molten soft agar (0.4%
Amyl agar, 48 °C). The mixture was then overlayed onto a solidiﬁed
nutrient agar made of 1.5% Amyl agar and nutrient broth. A volume of
10ml diluted phage samples were dropped onto the agar lawn in tri-
plicate, air dried and incubated at 37 °C overnight. Samples giving rise
to 3–30 plaques were used for phage viability calculation.
2.5. Powder dispersibility
In vitro aerosol performance of the phage powders was assessed at 0,
1, 3 and 12months storage. An Osmohaler™ coupled to a USP stainless
steel throat and a multi-stage liquid impinger (MSLI) was operated at
100 L/min for 2.4 s. A sample mass of 20 mg was weighed into a size 3
hydroxypropyl methylcellulose capsule (Capsugel, NSW, Australia).
The capsule ﬁlling was carried out in a humidity controlled box (17%
RH) while the dispersion was conducted at RH of 50 ± 5% and
20 ± 5 °C. SMB was used as the rinsing solvent to determine the viable
phage deposition proﬁles. Experiments were performed in triplicate.
The lower cutoﬀ diameters of the MSLI stages 1–4 at 100 L/min are
10.1, 5.3, 2.4 and 1.32mm, calculated with the adjustment equations
given in Appendix XII C of the British Pharmacopoeia. The ﬁne particle
fraction (FPF) was deﬁned as the mass fraction of particles with an
aerodynamic diameter ≤ 5.0 mm with respect to the total recovered
dose.
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2.6. Statistical analysis
One-way analysis of variance (ANOVA) and unpaired two-sample t
test at a conﬁdence level of 95% were employed to identify any sta-
tistical signiﬁcance in particle size and phage deposition. A p value
of< 0.05 was considered statistically signiﬁcant.
3. Result and discussion
3.1. Powder characterization
3.1.1. Phage and particle morphology
Fig. 1 shows the SEM images of the spray dried powders. The par-
ticles are generally spherical with wrinkled surfaces. In our previous
study [14], signiﬁcant particle fusion was noted for formulations con-
taining 80% trehalose and 20% leucine. By increasing the amount of
leucine to 30% and 40%, no particle fusion was noted in the present
study, indicating that a higher content of leucine resulted in better
coating of the particles. There was no visual diﬀerence between pow-
ders containing diﬀerent phages and diﬀerent amounts of leucine (30%
and 40%). The morphologies of the phage particles in the powders
stored under desiccation were also examined and no signiﬁcant changes
were found (data not shown).
3.2. Particle size
The volume median diameters (VMD) and span of the particles are
presented in Table 2. The results were in accordance with the SEM
images, with most particles falling within the inhalable size fraction of
less than 5 µm. No signiﬁcant diﬀerence was noted in the particle size
between the two formulations for the same phage, while the same
formulation composition containing PEV40 was signiﬁcantly larger
than that containing PEV2 (p < 0.01). Such diﬀerences could be due to
batch to batch variation, such as small variations in the buﬀer and
excipient compositions, setting of the atomizer during the spray drying
process, and small diﬀerences in the ambient temperature. It is also
noteworthy that the size obtained by laser diﬀraction is an optical
diameter which is susceptible to changes in particle morphology.
3.3. Powder crystallinity
The XRD proﬁles of spray dried leucine and matrix containing 30%
and 40% leucine are shown in Fig. 2a. The XRD traces for powders
stored after 12month were similar to those obtained for the freshly
produced powders (data not shown). For the same excipient composi-
tions, similar results were obtained for the two phages. Therefore, only
results for the PEV2 (F1 and F3) were reported. The crystalline nature
of spray dried pure leucine was conﬁrmed in the XRD measurements.
For powder matrices containing trehalose and leucine, the appearance
of both crystalline peak and broad halo pattern indicated the presence
of crystalline and amorphous materials. Most of the peaks noted in the
formulations were aligned with the crystalline peaks of spray dried
leucine alone, suggesting that the crystallinity of the powder matrices
was due to the leucine component. This is conﬁrmed in the Raman
measurement (Fig. 2b) that only crystalline leucine and amorphous
Fig. 1. SEM images of F1–F4.
Table 2
Optical particle size distribution and titer loss of phage in the solution and freshly pro-
duced powders. Plus/minus error is the standard deviation (n=3).
Formulation # VMD (µm) span Titer loss in
solution (log10
pfu/ml)
Titer loss in
freshly
produced
powders (log10
pfu/ml)
F1 (T70L30) 2.09 ± 0.11 1.73 ± 0.13 0.19 ± 0.16 0.77 ± 0.17
F2 (T60L40) 2.01 ± 0.03 1.57 ± 0.03 0.61 ± 0.10 0.67 ± 0.10
F3 (T70L30) 2.88 ± 0.12 1.93 ± 0.31 0.22 ± 0.11 0.18 ± 0.09
F4 (T60L40) 3.11 ± 0.09 1.93 ± 0.18 0.22 ± 0.07 0.28 ± 0.06
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trehalose were detected in all four formulations. The results agree with
that reported in Feng et al. [24] that the leucine was purely crystalline
for formulations with a leucine mass fraction larger than 25%.
3.4. Thermal analysis
The thermal behavior of phage powders obtained by DSC and TGA
analysis is shown in Fig. 3. Both formulations showed glass transition
temperature (Tg) of trehalose at ∼100 °C (Fig. 3a). as discussed in our
previous work [13], the large endothermic peak at 210–260 °C was
Fig. 2. (a) XRD proﬁles of the spray dried pure leucine and formulations containing 30% (F1, F3) and 40% (F2 and F4) leucine. (b) Raman spectra of reference materials, crystalline
trehalose dihydrate (c-Tre), spray dried amorphous trehalose (a-Tre), crystalline L-leucine (c-leu) and amorphous leucine (a-leu), and spray dried phage powders.
Fig. 3. (a) DSC and (b) TGA curves for formulations containing 30% (solid lines) and 40% (broken lines) leucine.
S.S.Y. Leung et al. European Journal of Pharmaceutics and Biopharmaceutics 127 (2018) 213–222
217
attributed to sublimation of leucine with the peak height/area increase
with increasing leucine content. This peak also corresponded to the
weight loss in the TGA results (Fig. 3b). The small endothermic peaks at
260–280 °C in the DSC traces, accompanying by a further weight loss
TGA data, were due to the decomposition or oxidation of trehalose.
3.5. Moisture sorption
An aim of the project is to evaluate whether a crystalline leucine
shell could reduce the moisture uptake by amorphous trehalose in the
spray dried phage powder formulations, as crystallization of the tre-
halose matrix has been shown to deactivate phage [22]. The moisture
absorption proﬁles of formulations containing 30% and 40% leucine are
shown in Fig. 4a. The onset of recrystallization was noted at 50% RH for
both formulations, indicating the increase of leucine content up to 40%
was not suﬃcient to form an impermeable crystalline leucine layer to
mitigate moisture uptake by the amorphous trehalose. The moisture
uptake kinetics of the two formulations at 60% RH (Fig. 4b) revealed
that trehalose recrystallization took place within 30min exposure, with
little diﬀerence between the two formulations. The results suggested
that the handling and storage of the phage powders below 20% RH
(ideally below 5%) would be necessary. Similar moisture sorption
proﬁles were obtained for powders stored after one year (data not
shown).
3.6. Surface composition
Table 3 shows the surface atomic concentrations of elements in pure
trehalose, pure leucine and the composite phage powders, as well as the
estimated molar fractions of trehalose and leucine at the particle sur-
face. The latter values are estimates and should only be interpreted
semi-quantitatively. Generally, more leucine in the formulation in-
creased the presence of leucine on the particle surface, with no sig-
niﬁcant diﬀerence noted between the two phages. For formulations
containing 30wt% (55mol%) leucine, the surface coverage of leucine
was 67–70mol%. When the leucine content increased to 40 wt%
(66mol%), the surface coverage increased to 82–89%. This high leucine
coverage on the surface could explain the surface corrugation as seen in
Fig. 1. However, the leucine shell may not have been continuous. This
could leave channels for the amorphous trehalose to uptake moisture
uptake and recrystallize when exposed to high humidity conditions as
observed in the DVS results.
3.7. Phage stability
After the spray drying process, a total of∼0.7 and∼0.2 log10 pfu/
ml titer reduction was observed in the PEV2 and PEV40 powders, re-
spectively, with no signiﬁcant diﬀerence noted between the two ex-
cipient combinations (Fig. 5). Since dry powder inhaler medications are
generally used at room conditions, adequate stability of the phage
powder formulations at room temperature is essential to avoid product
degradation prior to use by the patient. In addition, one of the major
drivers for the development of phage dry powder formulation is to
achieve easier storage, transport and administration. Formulations that
are stable at room temperature would be favorable as cold-chain sto-
rage could be diﬃcult to achieve in the developing world and during
transportation. Therefore, the spray dried powders were transferred
into two loosely capped glass vials, then placed inside vacuum sealed
package and stored at two temperatures, 4 °C and 20 °C, to assess the
eﬀect of temperature on the stability of phage powders.
The titer reduction was determined relative to the titer measured in
the liquid feedstock for spray drying. There was no further titer re-
duction noted for PEV2 phages containing 30% leucine up to a year at
both storage temperatures (p > 0.05). On the other hand, formulations
containing 40% leucine were found to be temperature dependent
(p≤ 0.05). While phage powders stored at 4 °C had no further loss
across the study, the titer reduction was gradually increased from
0.67 ± 0.10 log10 pfu/ml to 1.54 ± 0.38 log10 pfu/ml after 1 year
storage at 20 °C. The gradual loss of phage could be due to further
dehydration of powders upon storage. The formulation compositions
had limited impact on the storage stability of PEV40 in the powder
form. A further loss of ∼0.7 log10 pfu was noted after three months.
The titer reduction dropped to 0.5 log10 pfu/ml at the 6month time
point, which is within the uncertainties in the plaque assay used to
determine the phage titer (± 0.5 log10 pfu/ml). After 12month sto-
rage, the titer reduction of PEV40 was comparable to that obtained at
the 3month time, indicating no further phage inactivation in these
powders. Overall, the titer reduction of PEV40 was only ∼1 log10 pfu/
ml at both storage temperatures. As powders were stored under vacuum
Fig. 4. (a) Vapor sorption proﬁles and (b) kinetic of moisture uptake at 60% RH for
formulations containing 30% (solid lines) and 40% (broken lines) leucine.
Table 3
Atomic concentrations of elements in pure trehalose, pure leucine and the composite
phage powders, and the elemental composition at the particle surface.
Compound/
Formulation #
Elemental composition (Atomic
concentration, %)
Mass Fraction at the
surface (mol%)
C O N S Cl Trehalose Leucine
Pure trehalose 55.82 44.08 0.00 0.08 0.04
Pure leucine 68.16 20.42 11.19 0.11 0.13
F1 59.96 33.77 4.97 0.48 0.22 32.9 67.1
F2 63.12 28.71 7.12 0.40 0.16 18.3 81.7
F3 60.60 33.03 5.40 0.43 0.21 29.6 70.4
F4 65.20 25.80 8.39 0.29 0.14 11.5 88.5
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and handled at RH < 20%, re-crystallization of trehalose, which has
been identiﬁed as the major mechanisms responsible for phage in-
activation [21], was prevented. This was supported by the similarity in
the powder morphologies, crystallinity and DVS proﬁles between the
fresh and stored samples.
Our results show reasonable stability of both the PEV2 (podovirus)
and PEV40 (myovirus), with less than 1 log10 pfu/ml storage loss at the
studied storage temperature. This is in contrast to the results reported
in Vandenheuvel et al. [21] who showed a higher storage temperature
(25 °C) could cause thermal instability of the embedded phages, with
the impact being more profound for the larger myovirus (Romulus) than
the smaller podovirus (LUZ19). However, Vandenheuvel et al. [21] also
highlighted a possibility of leakage of the desiccator in which the Ro-
mulus phage powder was stored, causing the larger titer reduction of the
myovirus. Nonetheless, the discrepancies in storage stability between
our study and Vandenheuvel et al. [21] could also be phage dependent.
3.8. In vitro aerosol performance
The deposition proﬁles, total recovery and viable respirable phages
(FPF≤ 5 µm) of F1-F4 after dispersing with an Osmohaler™ at 100 L/
min for 2.4 s of the 0, 3, 6 and 12month old samples are depicted in
Fig. 6 (PEV2) and 7 (PEV40). While the recovery of trehalose was in the
range of 85–110% (data not shown), the recovery of viable phage
ranged from 12 to 117% with the majority of the dispersion experi-
ments falling at the low end (< 50%). The low recovery may be due to
phage inactivation upon impaction with the interior wall of the capsule,
inhaler and MSLI during the dispersion process. Dispersion experiments
of phage powders at a lower ﬂow rate, 60 L/min, were performed to test
this hypothesis. The recovery was found to be in the range of 30–60%
(data not shown), indicating either the low ﬂow rate dispersion caused
phage inactivation or phage inactivation upon dispersion was not the
main cause of the low recovery. Known titer phage suspension (105 pfu/
ml) of similar order to the phage titer detected in the dispersion tests
was used to rinse the capsule, device, adaptor, throat, all stages of the
MSLI and ﬁlter as for the real dispersion tests. Then plaque assay was
performed on the collected phage suspensions to conﬁrm the impact on
phages when they come into contact with the parts in the dispersion
tests. Negligible diﬀerences were observed between the known phage
suspension and those after rinsing for all parts, indicating that phages
were not adhered or deactivated during the handling process. None-
theless, the plaque assay generally has an accuracy of± 0.5 log10 pfu/
ml, which could cause variability in the recovery of phage.
Compared with our previous results which contained 20% leucine in
the powder formulations [14], the deposition of viable phage in the
capsule and device were signiﬁcantly lower in the present study (gen-
erally∼ 10%, with a few cases∼ 20%). As leucine is a surface active
compound and the surface coverage of leucine was>67%, the amount
of phage residing on the surface might be reduced, resulting in fewer
phage detaching from the powders upon impaction inside the capsule
and device. Comparing the two studied phages, the PEV2 phages had a
higher capsule and device deposition than the PEV40 phages. This
could be because more PEV2 phages were on the surface than the
PEV40 phages. As phage particles are essentially composed of a stable
protein capsule enclosing the genomic materials, they tend to reside at
the surface of the particle matrices during the drying process due to
their amphiphilic properties [27,28]. However, the rate of diﬀusion of
phage from the surface to the center would depend on the proportion of
hydrophobic to hydrophilic amino acids of their protein coat. Only a
small portion of phages was deposited on the adaptor, throat and Stage
1 of the MSLI. In most cases, the majority of the viable phage deposited
on Stage 3 and 4 and gave high FPF values> 40% for both formulations
and both PEV2 and PEV40 phages. No speciﬁc trends were observed in
the deposition proﬁle with the storage time for both formulation
compositions and phages.
The corresponding in vitro ﬁne particle dose (FPD) of phage, quan-
tiﬁed as the number of viable phages embedded in particles smaller
than aerodynamic diameter 5 µm, is shown in Fig. 8. The total ﬁne
particle dose of PEV2 phages was of the order of 107 pfu, which was 100
times higher than our previous study [14] caused mainly by the in-
creased titer of viral stocks (from 109 to 1011 pfu/ml). This indicates
that the more concentrated samples examined here did not result in
more damage in the production and storage process. In fact, there have
been studies with viruses indicating that a higher starting titer leads to
greater stability [29]. There were no signiﬁcant diﬀerences in the ﬁne
particle dose of viable phage noted for F1 up to 12month storage, ex-
cept signiﬁcantly lower values were obtained at 6month for powder
stored at 20 °C. Signiﬁcantly lower ﬁne particle dose of viable phage
was noted for F2 stored at 20 °C, with the dose decreasing gradually
from 7.5 log10 pfu to 6.4 log10 pfu in one year. Despite a signiﬁcantly
lower ﬁne particle dose being also obtained for F2 stored at 4 °C at
certain time points, the diﬀerence was within 0.5 log10 pfu which lies
within the uncertainties of the plaque assay.
The freshly produced PEV40 powder had a ﬁne particle dose of
107 pfu. Both formulations had a reduced ﬁne particle dose of phage at
both storage temperatures. The reduction was more profound for for-
mulations containing 30% leucine (F3), decreasing gradually from 7.4
log10 pfu to 6.3 log10 pfu and 6.1 log10 pfu for powders stored at 20 °C
and 4 °C, respectively. For formulations containing 40% of leucine
stored at 20 °C, the ﬁne particle dose of PEV40 had a ∼0.5 log10 pfu
Fig. 5. Phage stability in F1–F4 formulations of phages PEV2 (A) and PEV40 (B) after storage under vacuum at 4 and 20 °C. Titer reductions at 0 (Fresh), 1, 3, 6 and 12months are relative
to the titer measured in the spray dryer liquid feedstock. Asterisk (*) denotes a statistically signiﬁcantly higher (p≤ 0.05) titer reduction compared with the freshly prepared powders.
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drop after one month storage and plateaued, except the 6month data
which had a much higher phage recovery than other time points as seen
in Fig. 7. A ∼0.5 drop was also noted for F4 stored at 4 °C, but the
reduction was gradual, with the 6month data being exceptional. The
reduced ﬁne particle doses of PEV40 phage were aligned with the titer
loss of the phage in the powder form (Fig. 5), which was∼1 log10 pfu.
The impacts of storage temperature on the phage stability and ﬁne
particle dose were found to be phage speciﬁc. Although a high pro-
duction loss was noted for the PEV2 phages (0.7 log10 pfu/ml for F1 and
0.8 log10 pfu/ml for F2), they were generally more stable than the
formulations containing PEV40 phages upon storage at both tempera-
tures. Such speciﬁcity could arise from the distribution of the phages
within the particles or interactions between the phages and the ex-
cipients. While studying the mechanisms responsible for the stabiliza-
tion eﬀect of the powder compositions would certainly be valuable for
future development of stable phage powder formulations, the stabi-
lizing mechanisms are likely highly complex and beyond the scope of
the present study. Nonetheless, we have demonstrated that our
proposed powder matrix was suitable to incorporate phages of two
diﬀerent morphologies (Podovirus and Myovirus) with acceptable sta-
bility and a combined loss of< 1 log10 pfu/ml during production and
storage for a period of 12months.
4. Conclusion
The inﬂuences of leucine content and storage temperature on the
long term stability of spray dried trehalose powders containing two
diﬀerent phages (Podovirus PEV2 and Myovirus PEV40) were studied. A
low production loss was noted for both the PEV2 (0.7–0.8 log10 pfu/ml)
and PEV40 (0.2–0.3 log10 pfu/ml) in phage numbers. Although leucine
did not form a continuous crystalline shell to protect the powders from
moisture sorption, storing the powders under vacuum condition de-
monstrated acceptable stability (≤1 log10 pfu/ml) at both 4 °C and
20 °C for a period of 12months. PEV2 phage powders stored at 4 °C
were stable for both formulations studied. While the formulation con-
taining a lower amount of leucine (30%) preserved the viability of
Fig. 6. The distribution proﬁles, total mass recovery and FPF of viable PEV2 phage. Data
presented as mean ± one standard deviation (n=3). All formulations were dispersed at
100 L/min for 2.4 s using the Osmohaler™. The aerodynamic cutoﬀ diameter of each stage
is quoted in parentheses.
Fig. 7. The distribution proﬁles, total mass recovery and FPF of viable PEV40 phage. Data
presented as mean ± one standard deviation (n=3). All formulations were dispersed at
100 L/min for 2.4 s using the Osmohaler™. The aerodynamic cutoﬀ diameter of each stage
is quoted in parentheses.
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PEV2 phages at 20 °C, a∼ 0.9 log10 pfu/ml storage loss was obtained
for the formulation containing 40% leucine after 1 year. The PEV40
phage formulations had inferior storage stability relative to the PEV2
phage ones. In general, a∼ 0.5 log10 pfu/ml storage loss was noted for
both formulations and storage temperatures after 1 year. The observa-
tions for the ﬁne particle dose of viable phages were consistent with the
phage stability in the powders. Despite the titer loss upon storage, the
total ﬁne particle dose of PEV2 and PEV40 phages was of the order of
106–107 pfu. In summary, the proposed simple formulations containing
only leucine and trehalose could preserve the PEV2 and PEV40 phages
in the powder form and achieve reasonable aerosol performance during
a long term storage period of twelve months at both 4 °C and 20 °C. This
is the ﬁrst study to demonstrate long term room temperature storage
stability of inhalable phage powders.
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